Rizzo A.; Ricci A.D.; Brandi G., Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2021, 6, pp. 217 - 224 [articolo]
Rizzo A.; Santoni M.; Mollica V.; Fiorentino M.; Brandi G.; Massari F., Microbiota and prostate cancer, «SEMINARS IN CANCER BIOLOGY», 2021, 1044, pp. 1 - 8 [articolo]
Rizzo A.; Brandi G., Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, Article number: 100354, pp. 100354 - 100360 [articolo]Open Access
Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G., Nivolumab: an investigational agent for the treatment of biliary tract cancer, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2021, 30, pp. 325 - 332 [articolo]
Rizzo A.; Brandi G., Novel targeted therapies for advanced cholangiocarcinoma, «MEDICINA», 2021, 57, Article number: 212, pp. 1 - 3 [articolo]Open Access
Rizzo A.; Ricci A.D.; Brandi G., Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer, «CANCERS», 2021, 13, Article number: 558, pp. 1 - 11 [articolo]Open Access
Rizzo A.; Ricci A.D.; Brandi G., Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, pp. 1 - 6 [articolo]Open Access
Rizzo A.; Brandi G., Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 547 - 554 [articolo]
Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G., Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2021, 1, pp. 1 - 3 [articolo]
Rovesti G.; Leone F.; Brandi G.; Fornaro L.; Scartozzi M.; Niger M.; Yoo C.; Caputo F.; Filippi R.; Casagrande M.; Silvestris N.; Santini D.; Faloppi L.; Palloni A.; Aglietta M.; Vivaldi C.; Cho H.; Lai E.; Fenocchio E.; Nichetti F.; Pella N.; De Lorenzo S.; Di Maio M.; Vasile E.; de Braud F.; Jeong J.H.; Aprile G.; Orsi G.; Cascinu S.; Casadei-Gardini A., Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index, «JOURNAL OF GASTROINTESTINAL CANCER», 2021, 1, pp. 1 - 10 [articolo]
Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G., Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities?, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 1239 - 1240 [articolo]
Tovoli F.; Dadduzio V.; De Lorenzo S.; Rimassa L.; Masi G.; Iavarone M.; Marra F.; Garajova I.; Brizzi M.P.; Daniele B.; Trevisani F.; Messina C.; Di Clemente F.; Pini S.; Cabibbo G.; Granito A.; Rizzato M.D.; Zagonel V.; Brandi G.; Pressiani T.; Federico P.; Vivaldi C.; Bergna I.; Campani C.; Piscaglia F., Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma, «LIVER CANCER», 2021, 10, pp. 370 - 379 [articolo]Open Access
Rizzo A.; Ricci A.D.; Brandi G., Recent advances of immunotherapy for biliary tract cancer, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 527 - 536 [articolo]
Brandi G.; Frega G.; Rizzo A., Second-line FOLFOX chemotherapy for advanced biliary tract cancer, «THE LANCET ONCOLOGY», 2021, 22, pp. e285 - e285 [replica/breve intervento]
Zhu, A. X.; Finn, R. S.; Kang, Y. -K.; Yen, C. -J.; Galle, P. R.; Llovet, J. M.; Assenat, E.; Brandi, G.; Motomura, K.; Ohno, I.; Daniele, B.; Vogel, A.; Yamashita, T.; Hsu, C. -H.; Gerken, G.; Bilbruck, J.; Hsu, Y.; Liang, K.; Widau, R. C.; Wang, C.; Abada, P.; Kudo, M., Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab, «BRITISH JOURNAL OF CANCER», 2021, 124, pp. 1388 - 1397 [articolo]Open Access
